Thus, despite the small sampling, our results confirm the possibility of using the concentration of cfDNA in blood plasma as an additional marker of renal cancer development and show that methylation of three genes, FHIT, APC, and RASSF1, in cfDNA can be used to develop renal cancer diagnostic tools. This evidence concerns the gene RASSF1 and renal carcinoma.